SUMMARY -Th ere is limited evidence showing that elevated arterial blood pressure in surgical patients may be associated with increased perioperative risk; however, cardiovascular instability frequently occurs during anesthesia. Th e most commonly used anesthetic agents, both intravenous and inhalation ones, produce a decrease in arterial blood pressure. Magnesium, acting as a natural calciumchannel blocker, induces direct and indirect vasodilatation, thus playing a role in the treatment of arterial hypertension. In this research, we assessed the eff ects of magnesium sulfate on cardiovascular stability in patients undergoing diverse planned surgical procedures (abdominal, orthopedic, urology) under general balanced anesthesia, who were diagnosed with arterial hypertension grade 1 and 2. Th e research encompassed 100 patients of both sexes, aged from 20 to 65. Immediately before induction of anesthesia with propofol, the patients in the experimental group (50 study subjects) received 30 mg/ kg bolus dose and magnesium sulfate infusion at 10 mg/kg/h, whereas the subjects in the control group (50 patients) were administered normal saline. Anesthesia was achieved and maintained with sevofl urane, fentanyl and rocuronium. Th e hemodynamic variables of mean arterial pressure and heart rate were measured every fi ve minutes, starting immediately before magnesium infusion. Statistical analysis of the categorized values of mean arterial pressure and heart rate revealed a statistically signifi cant between-group diff erence at 60 th and 90 th minute of anesthesia. In conclusion, magnesium sulfate as an adjuvant to anesthesia in patients with arterial hypertension reduces hemodynamic changes during anesthesia.
Introduction
Although recent developments in technical and procedural aspects of anesthesiology have allowed substantial advancement of surgery, unavoidable anesthesia-related risks such as perioperative morbidity and mortality still remain a problem even in the 21 st century 1 . Accordingly, anesthesiologist plays an important role as a perioperative physician responsible for preoperative assessment, patient preparation, planning and selection of optimal anesthetic technique, and appropriate pharmacological agents.
Preoperative indicators of cardiovascular risk in non-cardiac surgery include ischemic heart disease, congestive heart failure, cerebrovascular disease, preoperative insulin therapy, and preoperative serum creatinine levels above 150 μmol/L 2 . Surgical factors affecting cardiac risks are strongly related to the urgency, extent, type and duration of the procedure itself 3 . It is believed that 15% of patients presenting for surgical procedures that require anesthesia suff er from arterial hypertension. Cardiovascular instability during anesthesia is more prevalent in these patients. Arterial hypertension associated with organ failure (ischemic heart disease, heart failure, renal failure) substantially increases the probability of perioperative cardiovascular complications. Establishing the type of hypertension, i.e. whether primary (essential) or secondary, is of great importance for further procedure. Conditions such as pheochromocytoma, hyperaldosteronism and renovascular hypertension require specifi c individual anesthesiologic approach 4 . According to the guidelines of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC), blood pressure is defi ned and classifi ed as follows: optimal (systolic <120 mm Hg, diastolic <80 mm Hg); normal (systolic 120-129 and/or diastolic 80-84); high normal (systolic 130-139 and/or diastolic 85-89); grade 1 hypertension (systolic 140-159 and/or diastolic 90-99); grade 2 hypertension (systolic 160-179 and/or diastolic 100-109); grade 3 hypertension (systolic >180 and/or diastolic >110); and isolated systolic hypertension (systolic >140, diastolic <90 mm Hg) 5 . Grade 1 and 2 hypertension by itself is not considered a risk factor for the occurrence of perioperative cardiovascular complications. In patients with grade 3 hypertension associated with apparent heart or kidney failure, the surgery should be delayed until reestablishment of normal arterial blood pressure and etiologic examination. If the surgery must be performed without delay, invasive intraoperative monitoring of arterial blood pressure should be provided while limiting oscillations of the mean arterial blood pressure to 20% of baseline values 4 . An optimal strategy that would maximally reduce the risks of perioperative cardiovascular complications implicates comprehensive preoperative cardiac evaluation of the patient along with appropriate pharmacological treatment regimen 3 . Patients suff ering from arterial hypertension are frequently exposed to extreme hypotension after induction of anesthesia, as well as to hypertensive stress-response to laryngoscopy and intubation, surgical incision and extubation. Postoperatively, inadequate pain relief can induce hypertensive response in such patients. Hypertensive episodes are often associated with arrhythmia and myocardial ischemia. Hypo-as well as hypertension can result in cerebrovascular complications 6 . Magnesium is of vital importance for human body. Th e majority of magnesium is absorbed in the small intestine. Kidneys play an important role in maintaining magnesium balance within the body. Administration of diuretics substantially increases magnesium excretion. Th e metabolism of magnesium is regulated through the action of a variety of hormones. Parathyroid hormone upregulates renal excretion of magnesium and decreases its intestinal absorption. Mineralocorticoids (aldosterone), thyroid hormones and insulin are responsible for increased renal excretion of magnesium, whereas adrenaline is associated with elevation of plasma magnesium levels. Increased serum magnesium concentration (hypermagnesemia) can occur in chronic infectious diseases, diabetic ketoacidosis, Addison's disease, atherosclerosis, and particularly in chronic renal insuffi ciency. Decreased serum magnesium level (hypomagnesemia) is often associated with enduring diarrhea, prolonged diuretic therapy, malabsorption syndrome, hyperaldosteronism and alcoholism. Hypomagnesemia is a common event in hypokalemic patients. Ionized free magnesium in serum is of crucial biological importance for mediating cellular ion channels and transport mechanisms. Magnesium plays a role in controlling calcium entry into the cells, thus aff ecting the cardiac smooth muscle tone, i.e. the tone of vascular smooth muscles 7 . Magnesium is considered the fourth most common cation within the whole of the human body and the second most important intracellular cation. It is a cofactor in the activation of a whole range of enzymes involved in biochemical reactions of protein synthesis. Magnesium manifests antinociceptive eff ects as a competitive antagonist of N-methyl-D-aspartate receptors. Competing with calcium ions, magnesium inhibits the release of presynaptic acetylcholine, thus enhancing the action of neuromuscular blocking agents. Magnesium sulfate depresses the central nervous system and reduces anesthetic requirements 8 .
Magnesium is regarded as a natural physiologic calcium antagonist. Patients subjected to major surgical procedure without magnesium supplementation are exposed to an increased risk of hypomagnesemia during the early postoperative period 9 . Magnesium is also used as an eff ective antiarrhythmic agent 10 . Some in vitro studies demonstrated that magnesium prevented catecholamine release from the adrenal medulla and adrenergic terminals, and produced coronary vasodilatation 11 . Ryu et al. demonstrated that the effects of magnesium sulfate in providing adequately controlled hypotension in patients undergoing ear surgery were the same as those of remifentanil 12 . Magnesium sulfate is applicable in therapy of hypokalemia, asthmatic attack and for protecting the heart muscle following ischemia 13 . Some recent studies strongly suggest the anti-infl ammatory eff ects of magnesium sulfate 14 . Th e concentration of total magnesium in the serum of an adult person ranges between 0.65 and 1.05 mmol/ L 7 . Magnesium preparations are usually well tolerated even if administered at large doses. In healthy individuals, plasma levels of magnesium ranging within the interval of 2-3.5 mmol/L are considered acceptable 15 . Th e aim of this research was to establish the eff ects of magnesium sulfate on cardiovascular stability in patients suff ering from arterial hypertension, who were subjected to non-cardiac surgery (elective abdominal, orthopedic and urology surgical procedures) under general balanced anesthesia.
Patients and Methods
In this double blind, prospective, randomized and controlled clinical trial, we assessed the eff ects of magnesium sulfate on cardiovascular stability in patients undergoing diverse planned surgical procedures (abdominal, orthopedic, urology) under general balanced anesthesia, who were diagnosed with grade 1 and 2 arterial hypertension. Th e research encompassed 100 patients of both sexes, aged from 20 to 65. Immediately before the induction of anesthesia with propofol (2 mg/ kg intravenously), the patients received 30 mg/kg bolus dose and magnesium sulfate infusion at 10 mg/kg/h (M group, n=50 patients) or saline placebo (K group, n=50 patients). Anesthesia was achieved and maintained with sevofl urane (1-3 vol%), fentanyl (5 μg/kg) and rocuronium (0.15 mg/kg every 30 minutes).
Pregnant women, patients with organ failure, patients with elevated potassium and magnesium levels, patients on calcium channel blocker therapy, and patients with AV block, myasthenia gravis or porphyria were not included in the research. Furthermore, patients suff ering massive intraoperative blood loss and those treated intraoperatively with antihypertensive drugs, antiarrhythmics or diuretics were excluded from the study.
Th e hemodynamic parameters of the mean arterial pressure (MAP) and heart rate (HR) were monitored and recorded every fi ve minutes. Baseline MAP had been measured before magnesium intravenous bolus was administered to the patient. Arterial blood pressure was measured noninvasively (Datex-Ohmeda S/5 2008).
All subjects gave their informed consent for participation in this study, approved by the local Ethics Committee.
Diff erences between the investigated groups were evaluated using Pearson c 2 -test, Fisher exact test, and Wilcoxon rank sum test (Mann-Whitney). All hypotheses were tested at the level of statistical significance of 0.05. Preoperative serum levels of magnesium ranged from 0.42 to 0.99 mmol/L in group K and from 0.56 to 1.06 mmol/L in group M (Table 1) . Postoperative serum magnesium values ranged from 0.4 to 0.9 mmol/L and from 0.75 to 3.51 mmol/L in group K and M, respectively (Table 2) .
Results

Th
Intravenous administration of magnesium sulfate bolus dose (30 mg/kg) resulted in MAP decrease in the majority of participants. After induction in anesthesia, patients from both groups manifested MAP decrease; however, diff erences between the groups were not statistically signifi cant. An increase in MAP values was recorded after endotracheal intubation in both groups, at a rate of 21% in group K and 18% in group M. In the majority of our patients, endotracheal intubation resulted in HR increase. Median HR increase as related to baseline values was 33% and 26% in groups K and M, respectively. Statistical analysis of categorized values of MAP and HR yielded a statistically signifi cant between-group diff erence at 60 th and 90 th minute of anesthesia. MAP values were within the range of hemodynamic stability (-20% to 20% decline from baseline values) in 21 (42%) group K patients and 38 (76%) group M patients (Fig. 1) . HR values were within the interval from -30% to 30% decline from baseline values in 26 (52%) group K patients and 37 (74%) group M patients (Fig. 2) .
According to minimum MAP values, it is apparent that the highest average drop was recorded among participants from group K with arterial hypertension grade 2. Diff erences between the group K arterial hypertension grade 2 and group M arterial hypertension grade 2 subgroups (K HTA 2 and M HTA 2) were . Th e participants suff ering from grade 2 arterial hypertension who were administered magnesium sulfate manifested a significantly lower MAP drop (Fig. 3) . Th e median extubation time after cessation of inhalation anesthetic was 7.8±3.33 minutes in group K and 7.1±2.96 minutes in group M. Th is extubation time diff erence was not statistically signifi cant (MannWhitney test, W=1395, p=0.31108, p>0.05). Th e mean pain intensity during the immediate postoperative period was assessed using the numerical point scale, which yielded 5.58±2.89 points in group K and 5.02± 2.35 in group M. With respect to this parameter, there were no statistically signifi cant diff erences between the groups (Mann-Whitney test, W=1401.5, p=0.28882, p>0.05).
Discussion
In our research, statistical analysis of categorized MAP values at diff erent time intervals revealed a statistically signifi cant diff erence between the groups in the 60 th minute of anesthesia. Altan et al. compared the eff ects of magnesium sulfate and clonidine on hemodynamic parameters during anesthesia and surgical procedure. MAP values recorded in patients receiving clonidine were significantly lower at all time intervals; however, the diff erence between the groups was not statistically significant 10 . Magnesium sulfate was used to prevent fl uctuation in arterial blood pressure during surgery for catecholamine-active glomus tumors in two patients. In one patient, sodium nitroprusside failed to provide adequate hemodynamic stability, which was established after the administration of magnesium sulfate. In the second patient, hemodynamic stability was successfully managed using magnesium sulfate as a single agent 20 . Magnesium sulfate proved eff ective in patients with subarachnoid hemorrhage due to ruptured aneurysm of cerebral vessels 21 .
K HTA 1 = patients with arterial hypertension grade 1 receiving saline placebo; K HTA 2 = patients with arterial hypertension grade 2 receiving saline placebo; M HTA 1 = patients with arterial hypertension grade 1 receiving 30 mg/kg bolus dose and magnesium sulfate infusion at 10 mg/kg/h; M HTA 2 = patients with arterial hypertension grade 2 receiving 30 mg/kg bolus dose and magnesium sulfate infusion at 10 mg/kg/h In the present study, cortisol, vasopressin and catecholamine plasma levels were not analyzed, but the interaction of magnesium sulfate and vasopressin is well known because hypersecretion of antidiuretic hormone (vasopressin) results in hypomagnesemia. High concentrations of antidiuretic hormone also caused vasoconstriction and consequential increase of blood pressure. Application of magnesium sulfate reduces the eff ects of hormone stress response during surgery 22, 23 . Ryu et al. demonstrated the eff ects of magnesium sulfate in providing adequately controlled hypotension to be the same as those of remifentanil. However, postextubation MAP and HR values were higher in participants administered remifentanil 12 . Th e question, whether magnesium sulfate can actually provide hemodynamic stability during anesthesia and under which dosage regimen, requires further research in order to be answered.
In conclusion, magnesium sulfate as an adjuvant to anesthesia in patients with arterial hypertension reduces hemodynamic changes during anesthesia.
